tbuckley/cabot-search huggingface dataset:
OP0152-PARE Starting A Disease Specific Youth Group on A National Level
Authors: J. Andersen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A high proportion of individuals living with lupus (SLE) are young women, aged 25 to 35. At this age, they are getting ready to “begin” life with partners, children, education and careers. For most of them, this all stops at the time of diagnosis. They have to adjust to a lifelong struggle with pain, fatigue, headaches, cognitive problems and strong medications. As a result of this autoimmune disease, it is for instance, no longer risk-free to bear a child. This has to be done in close co-operation with various health professionals, and for some women, it is not an option at all. <h3>Objectives</h3> To help these young people to understand their disease and inspire them to live a full life, despite of coping with this incurable disease. A better understanding of the disease makes it easier to take control of treatment, and thereby having a more fulfilling life. <h3>Methods</h3> The goal was to start a youth group within our mother organisation. Although we already have a working and active SLE group in Denmark, that has existed for 22 years, we found out, that the young people were not joining in. The issues of a lupus patient changes considerably from when you are in your 20s, to your 50s (where most of our members were at that time). As a young person, you may not be comfortable with talking about your sex life with “older” ladies. We started with a theme day about sex and partnership, only for young people, and their spouses – and this was a great success. <h3>Results</h3> Out of this day, a Facebook group for young people (ages 18–35) was created, where the young people can discuss everything they want to. There are no taboos and people support each other with good advice or a shoulder to cry on. Besides the Facebook group, we now have a youth day with changing themes on our schedule every year. We have one person dedicated to the youth activities and this person also has a seat in our mother organisation, whereby youth issues are implemented in all our activities. <h3>Conclusions</h3> We now have a well functioning and active youth group, where young people with lupus can support each other and raise the issues important to them. <h3>References</h3> The web page of our mother association “SLE-diagnosenetværk DK”: http://sle.dk and the Facebook group “Unge med Lupus/SLE”: https://www.facebook.com/groups/1398750663726027/ <h3>Acknowledgement</h3> The support of the Danish arthritis association “Gigtforeningen” has made it possible to fund our youth projects without having to go fundraising ourselves, which we are very grateful for. <h3>Disclosure of Interest</h3> None declared
The Problem of Funding Off-label Deep Brain Stimulation
Authors: P. Justin Rossi, James Giordano, Michael S. Okun
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
SAT0306 How Does Cigarette Smoking Affect Sjögren's Syndrome?
Authors: J.C. Sarmiento-Monroy, N. Molano-González, M. Rodríguez-Jiménez, R.D. Mantilla, A. Rojas-Villarraga, J.-M. Anaya
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cigarette smoking has been found to play a pathogenic role in several autoimmune diseases. However, data about its influence on Sjögren9s syndrome (SS) is scarce [1,2]. <h3>Objectives</h3> To assess the impact of cigarette smoking on patients with SS. <h3>Methods</h3> This was a cross-sectional study in which consecutive patients with SS (2002 AECG) followed at a single center were included. Smoking status (ever) together with additional environmental factors and clinical and laboratory characteristics were assessed. Bivariate analysis and the mixed-cluster methodology based on multivariate descriptive methods were employed to analyze data. <h3>Results</h3> Out of a total of 277 patients, 94% were women. The mean age of patients was 51.2 ± 12.5 years, and the mean duration of the disease was 7.1 ± 7.1 years. By Chisholm and Mason classification, 93% of patients were positive for a minor salivary gland biopsy. Anti-Ro and anti-La antibodies were present in 65% and 40% respectively (by ELISA). Polyautoimmunity was registered in 43% of patients. Smokers showed a longer duration of the disease and were mostly men. Cigarette smoking was associated with parotidomegaly (OR: 1.9; 95%CI 1.05–4.3; p=0.03), polyautoimmunity (OR: 1.9; 95%CI 1.2–3.3; p=0.009), acid peptic disease (OR: 2.3; 95%CI 1.4–4.0; p=0,0008), and coffee consumption (OR: 1.7; 95%CI 0.98–3.6; p=0.04). In order to clarify whether the observed associations were influenced by gender or coffee consumption, 4 clusters were built: 1) men with a high frequency of smoking and coffee consumption (5.6%), 2) women who exclusively reported coffee consumption (42%), 3) women who all drank coffee and smoked cigarettes (30%) and 4) women with no coffee consumption but a third had been exposed to tobacco (22.4%). Cluster 2 patients were statistically less prone to present factors found in the bivariate analysis suggesting that coffee consumption may counteract the harmful effects of smoking. <h3>Conclusions</h3> Our results indicate that cigarette smoking has significant effects on SS expression, which could be modified by coffee consumption. <h3>References</h3> Manthorpe R, et al. Ann Rheum Dis 2000;59(1):54–60. Karabulut G, et al. Mod Rheumatol 2011;21(6):602–7. <h3>Disclosure of Interest</h3> None declared
Blood brain barrier permeability to temozolomide
Authors: Kathleen Kelly, Manuel R. Sacapano, Ksenia Prosolovich, John Ong, Keith Black
Journal: Cancer Research (2005)

1411  INTRODUCTION: Since the blood-brain barrier (BBB) inhibits drug delivery, transporting pharmacological agents across the BBB is a limiting factor in effective chemotherapy against intracranial neoplasms. The molecular properties of each individual chemotherapeutic agent are unique thus allowing some drugs to be more permeable to the BBB than others. This study assesses how effectively temolozolomide gets transported across the BBB. METHODS: Intravenous injection of radiolabeled temolozolomide was performed on nude mice via tail vein. One hour post-injection of the temozolomide mice were sacrificed at different time intervals. Blood samples were taken. The brain along with the liver and spleen were harvested and homogenized. The homogenate of each organ was then measured for amount of radioactivity using a scintillation counter. RESULTS: Radioactivity was not only measurable in the liver and spleen as expected but was demonstrated to be present in the brain parenchyma as well. Interestingly temozolomide in the brain decreased over time while increased over time in the liver. CONCLUSIONS: Temozolomide appears to be permeable to the BBB and thus has significant implications on its use to treat brain tumors. Since chemotherapeutic agents that have the ability to cross the BB are currently in use, it would be of great interest to further determine if increasing the delivery of these drugs as well as those that do not readily cross the BBB could lead to more efficacious treatment. Our laboratory is currently investigating the possibility of increasing BBB permeability through endothelial cell modulator agents or through vasoactive modulator agents.
THU0281 Artesunate Inhibits Type I Interferon Induced Production of Macrophage Migration Inhibitory Factor in Patients with Systemic Lupus Erythematosus
Authors: X. Feng, W. Chen, L. Sun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Macrophage migration inhibitory factor (MIF) is a key regulator of both atherosclerosis and systemic lupus erythematosus (SLE), yet the factors participating in its production remain unclear. <h3>Objectives</h3> In this study, the relationship between type I interferon (IFN) and MIF levels in SLE patients were examined, and the effect as well as the mechanism of artesunate (ART), an anti-malarial agent extracted from Chinese herbs, on the regulation of MIF were explored. <h3>Methods</h3> Serum and peripheral blood cells from SLE patients and healthy controls were collected, with MIF levels measured by ELISA and type I IFN inducible gene expressions detected by real-time PCR. Associations between two factors were assessed by Spearman correlation analysis. ART at different concentrations was added to human umbilical vein endothelial cells (HUVECs) cultures with or without prior IFNα-1bstimulation and to SLE peripheral blood mononuclear cells (PBMC) cultures, with dexamethasone or fludarabine, a selective inhibitor of signal transducer and activator of transcription (STAT) 1, applied as positive treatment controls. Protein levels of STATs and phosphorylated (p-) STATs in HUVECs were determined by western blotting. <h3>Results</h3> Serum MIF levels were elevated in SLE patients and positively associated with disease activity (<i>r</i> =0.86, <i>p</i> &lt;0.0001) and accumulated damage (<i>r</i> =0.34, <i>p</i> =0.048). Meanwhile, increased MIF levels were closely associated with IFN scores in SLE patients (<i>r</i> =0.74, <i>p</i> =0.0002). <i>In vitro</i> experiments showed that IFNα-1b had a direct impact on MIF production. ART could inhibit IFN inducible gene (LY6E and ISG15) expressions in HUVECs and PBMC cultures, and suppress IFNα-1b induced MIF production. Over-expression of p-STAT1, but not p-STAT3 or STAT5, was detected after IFNα-1b stimulation, which was completely reversed at the presence of ART. <h3>Conclusions</h3> MIF could be regulated by type I IFN in SLE patients. ART counteracts the effect of IFNα to inhibit MIF production by blocking STAT1 phosphorylation, thus may have therapeutic potential for SLE-associated atherosclerosis. <h3>Disclosure of Interest</h3> None declared
High Dose Methotrexate (HD MTX at 2 gr/sqm x 4) Associated to Extended Intrathecal (IT) Chemotherapy Is Effective for Prevention of Central Nervous System (CNS) Relapse in Childhood ALL Treated with BFM Systemic Therapy.
Authors: Valentino Conter, Carmelo Rizari, Maria Grazia Valsecchi, Daniela Silvestri, Maurizio Aricò, Elena Barisone, Fiorina Casale, Giulio De Rossi, Franco Locatelli, Luca Lo Nigro, Chiara Messina, Concetta Micalizzi, Andrea Pession, Rosanna Parasole, Roberto Rondelli, Nicola Santoro, Anna Maria Testi, Momcilo Jankovic, Giuseppe Basso, Andrea Biondi, Giuseppe Masera
Journal: Blood (2005)
Effects of Dabigatran, a Direct Thrombin Inhibitor, as Compared to the Direct Factor Xa Inhibitors, Rivaroxaban and Apixaban, on Tissue Factor-Induced Human Platelet Aggregation in Platelet Rich Plasma.
Authors: Joanne van Ryn, Monika Kink-Eiband, Norbert Hauel, Henning Priepke, Wolfgang Wienen
Journal: Blood (2007)
Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II
Authors: Tanyanan Tanawuttiwat, Kathryn R. Wagner, Gordon Tomaselli, Saman Nazarian
Journal: JAMA Cardiology (2016)

This study quantitates the baseline prevalence and longitudinal incidence of conduction abnormalities and left ventricular dysfunction during intermediate-term follow-up of a cohort of patients with myotonic muscular dystrophy.
Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.
Authors: Olga Wachowski, Martin Zimmermann, Birgit Burkhardt, Olaf Determann, Ulrike Meyer, Peter Kaatsch, Georg Mann, Reza Parwaresch, Hansjoerg Riehm, Martin Schrappe, Alfred Reiter
Journal: Blood (2005)
A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma
Authors: Nishitha M. Reddy, Rhea M Simons, Meghan E Caldwell, Heidi Chen, Madan Jagasia, David S Morgan, Steven I. Park, John P Greer, Kristy L. Richards
Journal: Blood (2012)
Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics
Authors: Xiaosong Huang, Weijie Lan, Philippe Parone, Raedun Clarke, Ramzey Abujarour, Megan Robinson, Miguel Meza, Sarah Raynel, Betsy Rezner, David Robbins, Tom Tong Lee, Daniel Shoemaker, Bahram Valamehr
Journal: Blood (2015)
Brexit—a perspective from the other side of the Channel
Authors: Gianluca Pellino, Francesco Pata, Valeria Farina, Caterina Foppa, Laura Gavagna, Pietro Maria Naccari, Sandro Pasquali, Francesco Pata, Gianluca Pellino, Bruno Sensi, Alessandro Sgro, Alberto Arezzo, Michele Rubbini, Mario Morino, Francesco Selvaggi, Giuseppe Sica
Journal: The Lancet (2016)
Veterans Affairs Proposed Rule for Advanced Practice Registered Nurses in the Operating Room
Authors: Nader N. Massarweh, Samir S. Awad
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Efficient Delivery of the A-Gamma Globin Gene in Human Hematopoietic and Non-Hematopoietic Cells by Cationic Phosphonolipid- and Lipophosphoramide-Mediated Transfection.
Authors: Daphne Koumbi, Jean C. Clement, Anna-Maria Psarra, Zili Sideratou, Jean-Jacques Yaouanc, Maria Chatzouli, Dimitris Loukopoulos, Panagoula Kollia
Journal: Blood (2007)
PTU-096 5 Year Gastrostomy Audit: The Benefits of a Nutrition Nurse Led Service: Abstract PTU-096 Table 1
Authors: E Pindard, T Marshall, P Neild
Journal: Gut (2016)

<h3>Introduction</h3> Percutaneous Endoscopic Gastrostomy (PEG) is usually the preferred method of providing enteral nutrition in those patients whereby oral nutrition is contraindicated or inadequate for more than four to six weeks. Yet it is an invasive procedure and not without complications. The National Confidential Enquiry into Patient Outcome and Death (NCEPOD, 2004) found (19%) of PEG procedures were futile or not indicated at all. Furthermore 30 days PEG related mortality was reported to be between 2% to 26%. It was therefore advised that clinicians need to ensure appropriateness of its usage and that patient selection is paramount. At our trust a Nutrition Nurse Specialist (NNS) assesses all adult patients referred for a gastrostomy. Complex patients are discussed with a Consultant Gastroenterologist or Gastroenterology Registrar. In the absence of the NNS a Gastroenterology Registrar reviews patients. <h3>Methods</h3> Data was collected prospectively, by the NNSs, on both inpatients and outpatients referred for gastrostomy between 1 April 2010 and 1 April 2015. Information recorded included indication for and source of referral, time to procedure, morbidity and 30 day mortality. <h3>Results</h3> Table 1 above shows the numbers of PEG, RIG (Radiologically Inserted Gastrostomy) and jejunostomy insertion, changes and removals. <h3>Morbidity</h3> During this period there were 5 infections at the tube site confirmed by positive culture (0.9%, reduced from 12.5% pre current NNS) 3 leakages resulting in peritonitis (0.5%) 1 bleeding post procedure -anticoagulation not held as per advice (0.2%) <h3>Mortality</h3> Overall 30 day mortality from any cause following gastrostomy was 5.6% (n = 31). 3.8% (n = 21) were in the RIG group and 2% (n = 11) were in the PEG group. 193 (35%) patients were referred for gastrostomy but did not go ahead with the procedure or had it deferred. With the cost of gastrostomy insertion of approximately £2000 (PEG/RIG) this has resulted in a cost saving to the trust of £386,000. <h3>Conclusion</h3> Despite on-going training indication for gastrostomy insertion is still not understood by referring teams. A NNS led service can reduce morbidity, mortality and procedure failure rate. Comparing data to pre current NNS appointment the total number of tube insertions has doubled however deferral rates remain the same. There was a 15% failure rate which has since decreased to 3%. Infection rate reduction, may be linked to the development of an education programme, development of nutrition link nurse role, competencies and policy. Improve knowledge on procedure and complications to reduce the number of inappropriate referrals. <h3>Disclosure of Interest</h3> None Declared
THU0618 Disease Activity during and after Pregnancy in Women with Juvenile Idiopathic Arthritis: Results from A Prospective Multicenter Study
Authors: K. Ursin, S. Lydersen, J. Skomsvoll, M. Wallenius
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Studies from the 1990s have demonstrated that the majority of women with juvenile idiopathic arthritis (JIA) experience decreased disease activity during pregnancy while about 50% flare post partum (1–3). However, these studies were retrospective studies without validated disease activity measures. DAS28 is a validated disease activity measure in women with JIA, and DAS28-CRP-3 is a validated disease activity measure during pregnancy in women with rheumatoid arthritis (4). <h3>Objectives</h3> The aim of this project was to prospectively study disease activity in women with JIA during pregnancy and until one year post partum with DAS28-CRP-3 as disease activity measure. <h3>Methods</h3> RevNatus is a Norwegian national research database, designed for the follow-up of women with inflammatory rheumatic diseases during and after pregnancy. The women have 6 or 7 visits at a rheumatology unit; before conception if possible (visit 0), in each trimester (visit 1–3), and 6 weeks, 6 months and 12 months post partum (visit 4–6). RevNatus included 135 fullterm pregnancies in 114 women with JIA between 2006 and 2015. To explore disease activity throughout pregnancy and until one year post partum, DAS28-CRP-3-values registrered at each visit were analyzed in a three level linear mixed model. <h3>Results</h3> Analyzing DAS28-CRP-3-values from 6 time points throughout and after pregnancy in 135 pregnancies in 114 women with JIA, we found that disease activity 6 weeks post partum was significantly higher than disease activity in first trimester (p=0,004), in third trimester (p=0,011) and 12 months post partum (p=0,015). Results are displayed in figure shown below. <h3>Conclusions</h3> In 135 pregnancies in women with JIA disease activity increased significantly from pregnancy to 6 weeks post partum, and then decreased significantly between 6 weeks and 12 months post partum. The results call for tight follow-up of women with JIA in the first weeks after delievery. <h3>References</h3> Ostensen M. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol. 1992;28(3–4):235–7. Epub 1992/10/01. Ostensen M. Pregnancy in patients with a history of juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34(7):881–7. Epub 1991/07/01. Musiej-Nowakowska E, Ploski R. Pregnancy and early onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis. 1999;58(8):475–80. Epub 1999/07/27. de Man YA, Hazes JM, van de Geijn FE, Krommenhoek C, Dolhain RJ. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(5):716–22. Epub 2007/05/29. <h3>Disclosure of Interest</h3> None declared
Human Milk Protein Prevents Infections in Preterm Infants
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience
Authors: Jeffrey S Barrett, Alena Y. Zhang, Karen A. Urtishak, Gwenn Danet-Desnoyers, Andrew J. Carroll, Stephen P. Hunger, Carolyn A. Felix
Journal: Blood (2011)